<DOC>
	<DOCNO>NCT02607293</DOCNO>
	<brief_summary>This Phase IV , prospective , observational , single arm , multicenter trial identify population high risk overstimulation associate sign symptom PCOS examine utility 12.5 international unit ( IU ) increment Gonal-f® new pen individualize controlled ovarian stimulation ( iCOS ) .</brief_summary>
	<brief_title>A Study Explore Correlation Between Symptoms Signs Polycystic Ovarian Syndrome ( PCOS ) Risk Over-response Ovarian Stimulation</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<criteria>Female subject age 20 35 year ( include ) Subjects undergoing ART treatment long GnRHa protocol GnRHant protocol + Gn + human chorionic gonadotropin ( hCG ) Subject write informed consent obtain understanding subject may withdraw consent time without prejudice future medical care Subjects undergoing ART treatment mild stimulation protocol Concomitant use Gonalf® clomiphene citrate With In vitro fertilisation ( IVF ) / Intracytoplasmic sperm injection ( ICSI ) history great equal ( &gt; = ) 3 time Known history poor ovarian response previous COS cycle IVF/ICSI , define less 4 oocyte retrieve history previous cycle cancellation prior oocyte retrieval due poor response poor ovarian reserve , Antral follicle count ( AFC ) less ( &lt; ) 5 7 Presence confirm suspected endometriosis Grade III IV Presence unilateral bilateral hydrosalpinx Using Gn stimulation period ( urinary FSH/human menopausal Gn , except recombinant luteinizing hormone ( rLH ) ) Known history recurrent miscarriage Any contradiction Gn/GnRH analogues Any major systemic disease per Investigator 's discretion precludes subject participation study According judgment Investigator , medical condition concomitant surgery/ medication would interfere evaluation study medication Simultaneous participation another clinical study</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Polycystic Ovary Syndrome</keyword>
	<keyword>Gonadotropin release hormone agonist ( GnRH-a )</keyword>
	<keyword>Gonal-f</keyword>
	<keyword>Assisted Reproductive Technology</keyword>
</DOC>